CD8A and AIDS: Therefore, to study in vivo the effect of the A40R deletion on the HIV-1-specific T-cellular immunogenicity elicited by the HIV/AIDS vaccine candidate MVA-B, we analyzed the HIV-1-specific CD4+ and CD8+ T-cell immune responses induced by MVA-B ΔA40R in Balb/c mice immunized with a DNA prime/MVA boost immunization regimen, as this protocol amplifies the levels of T- and B-cell responses, while the homologous MVA prime/MVA boost immunization triggers lower responses [4,16].